0.4654USD-24.69%Mkt Cap: 842470 USDP/E: —Last update: 2026-05-26
Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. Protagenic Therapeutics, Inc. was founded in 2…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap842.47K USD
Enterprise Value2.90M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-5.53M USD
Revenue/Share—
Last Price0.4654 USD
Fiscal Year End—
MR QuarterDec 2025
Employees1
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.07
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-0.50
EPS (TTM)-13.13
EPS (Forward)-0.58
52W Range
0.25004% of range6.200
52W High6.200 USD
52W Low0.2500 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-545.36%
ROA-282.49%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.22M USD
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt1.78M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio—
Quick Ratio—
Book Value/Sh-1.2370 USD
Cash/Share1.222 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJul 27, 2016
Splits
Last Split1:14
Split DateMay 5, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.1.81M
Float—
Insiders3.84%
Institutions4.64%
Short Interest
Short Ratio0.6d
Short % Float3.30%
Short % Out.3.19%
Shares Short61.71K
Short (prev mo.)56.97K
Technical
SMA 500.6457 (-27.9%)
SMA 2001.670 (-72.1%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)7.51K
Avg Vol (10d)5.34K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—